Next Article in Journal
Exercise to Reduce Anthracycline-Mediated Cardiovascular Complications in Breast Cancer Survivors
Previous Article in Journal
Impact of Split Dosing the First Rituximab Infusion in Patients with High Lymphocyte Count
Previous Article in Special Issue
Feasibility of Stereotactic Body Radiation Therapy on Unresectable Stage III NSCLC with Peripheral Primary Tumor: A Prospective Study (GFPC 01-14)
Review

Neoadjuvant Therapy in Lung Cancer: What Is Most Important: Objective Response Rate or Major Pathological Response?

by and *
Cancer Center, The First Hospital of Jilin University, 71 XinMin Street, Changchun 130021, China
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2021, 28(5), 4129-4138; https://doi.org/10.3390/curroncol28050350
Received: 22 August 2021 / Revised: 30 September 2021 / Accepted: 9 October 2021 / Published: 13 October 2021
Lung cancer is the most fatal and frequently diagnosed malignant tumor. Neoadjuvant therapy is a promising approach for prolonging survival and increasing the chance of cure rates for patients with potentially resectable disease. Currently, many therapeutic alternatives, including chemotherapy, targeted therapy, and immunotherapy, are continually being explored to enrich the content of neoadjuvant therapy. However, neoadjuvant therapy remains to have no unified evaluation standards. Overall survival (OS) is the “gold standard” for evaluating the clinical benefit of cancer treatment, but it needs years for a reliable evaluation. Hence, researchers need to identify surrogate endpoints that can predict OS accurately and reliably without long follow-up periods. In this review, we describe the research progress of different neoadjuvant therapies and explore their response evaluation, aiming to identify stronger predictors of OS. View Full-Text
Keywords: non-small cell lung cancer; neoadjuvant therapy; objective response rate; major pathological response non-small cell lung cancer; neoadjuvant therapy; objective response rate; major pathological response
MDPI and ACS Style

Chen, X.; Ma, K. Neoadjuvant Therapy in Lung Cancer: What Is Most Important: Objective Response Rate or Major Pathological Response? Curr. Oncol. 2021, 28, 4129-4138. https://doi.org/10.3390/curroncol28050350

AMA Style

Chen X, Ma K. Neoadjuvant Therapy in Lung Cancer: What Is Most Important: Objective Response Rate or Major Pathological Response? Current Oncology. 2021; 28(5):4129-4138. https://doi.org/10.3390/curroncol28050350

Chicago/Turabian Style

Chen, Xi, and Kewei Ma. 2021. "Neoadjuvant Therapy in Lung Cancer: What Is Most Important: Objective Response Rate or Major Pathological Response?" Current Oncology 28, no. 5: 4129-4138. https://doi.org/10.3390/curroncol28050350

Find Other Styles

Article Access Map by Country/Region

1
Back to TopTop